Coagulation Disorders Associated with Neoplastic Disease

  • R. H. Steingart
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 108)


Hemorrhagic, thrombotic, and embolic complications occur frequently in cancer patients. Diverse hemostatic alterations, including impaired plasma coagulation, platelet abnormalities, and vascular disorders, account for these defects.


Chronic Lymphocytic Leukemia Disseminate Intravascular Coagulation Acute Promyelocytic Leukemia Acquire Immune Deficiency Syndrome Disseminate Intravascular Coagulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Trousseau A (1865) Phlegmasia alba dolens. Clinique medicale de l’Hotel-dieu de Paris, London. New Sydenham Society 3: 94Google Scholar
  2. 2.
    Sack GH, Levin J, Bell W (1977) Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms. Clinical, pathologic and therapeutic features. Medicine (Baltimore) 56: 1–37Google Scholar
  3. 3.
    Bick RL (1978) Alterations of hemostasis with malignancy. Semin Thromb Hemost 5: 1–26PubMedGoogle Scholar
  4. 4.
    Schafer AI (1985) The hypercoagulable states. Ann Intern Med 102: 814–828PubMedGoogle Scholar
  5. 5.
    Sun NC, McAfee WM, Gibert JM et al. (1979) Hemostatic abnormalities in malignancy, a prospective study of one hundred and eight patients. Am J Clin Pathol 71: 10–16PubMedGoogle Scholar
  6. 6.
    Rickles FR, Edwards RL (1983) Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 62: 14–31PubMedGoogle Scholar
  7. 7.
    Gralnick HR, Sultan C (1975) Acute promyelocytic leukemia: haemorrhagic manifestation and morphologic criteria. Br J Haematol 29: 373–376PubMedCrossRefGoogle Scholar
  8. 8.
    Drapkin RI, Gee TS, Dowling MD et al. (1978) Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 41: 2482–2490CrossRefGoogle Scholar
  9. 9.
    Goldsmith GH Jr (1984) Hemostatic disorders associated with neoplasia. Ratnoff OD, Forbes CD (eds) Disorders of hemostasis. Grune and Stratton, Orlando, pp 351–363Google Scholar
  10. 10.
    Davidson JR, McNicol GP, Frank GC (1969) Plasminogen-activator producing tumor. Br Med J [Clin Res] 1: 88–91CrossRefGoogle Scholar
  11. 11.
    Bellone JD, Kunicki TH, Aster RH (1983) Immune thrombocytopenia associated with carcinoma. Ann Intern Med 99: 470–472PubMedGoogle Scholar
  12. 12.
    Perkins HA, Mackenzie MR, Fudenberg HH (1970) Hemostatic defects in dysproteinemias. Blood 35: 695–707PubMedGoogle Scholar
  13. 13.
    Kitchens CS (1984) The purpuric disorders. Semin Thromb Hemost 10: 173–189PubMedCrossRefGoogle Scholar
  14. 14.
    Kyle RA, Bayrd ED (1975) Amyloidosis. Review of 236 cases. Medicine (Baltimore) 54: 271–299Google Scholar

Copyright information

© Springer-Verlag Berlin·Heidelberg 1988

Authors and Affiliations

  • R. H. Steingart
    • 1
  1. 1.Division of Hematology/OncologyBaystate Medical CenterSpringfieldUSA

Personalised recommendations